JP2008539794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539794A5 JP2008539794A5 JP2008512536A JP2008512536A JP2008539794A5 JP 2008539794 A5 JP2008539794 A5 JP 2008539794A5 JP 2008512536 A JP2008512536 A JP 2008512536A JP 2008512536 A JP2008512536 A JP 2008512536A JP 2008539794 A5 JP2008539794 A5 JP 2008539794A5
- Authority
- JP
- Japan
- Prior art keywords
- biological sample
- level
- therapeutic agent
- biomarker
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68258205P | 2005-05-18 | 2005-05-18 | |
| US60/682,582 | 2005-05-18 | ||
| US74928505P | 2005-12-09 | 2005-12-09 | |
| US60/749,285 | 2005-12-09 | ||
| PCT/US2006/019414 WO2006125143A2 (en) | 2005-05-18 | 2006-05-18 | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012272271A Division JP2013057686A (ja) | 2005-05-18 | 2012-12-13 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008539794A JP2008539794A (ja) | 2008-11-20 |
| JP2008539794A5 true JP2008539794A5 (cg-RX-API-DMAC7.html) | 2009-09-24 |
| JP5208730B2 JP5208730B2 (ja) | 2013-06-12 |
Family
ID=37022828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512536A Expired - Fee Related JP5208730B2 (ja) | 2005-05-18 | 2006-05-18 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
| JP2012272271A Pending JP2013057686A (ja) | 2005-05-18 | 2012-12-13 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012272271A Pending JP2013057686A (ja) | 2005-05-18 | 2012-12-13 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8337851B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1894012A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5208730B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006247067B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2608751A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006125143A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006247067B2 (en) * | 2005-05-18 | 2012-06-07 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling |
| US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| NZ592159A (en) | 2005-12-09 | 2012-12-21 | Amc Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| EP1987161A4 (en) * | 2006-01-20 | 2009-06-24 | Univ Mcgill | METHOD FOR IDENTIFYING CD40-SENSITIVE CELLS |
| AR060487A1 (es) | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
| ES2318616T3 (es) * | 2006-06-01 | 2009-05-01 | Cellzome Ag | Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70. |
| CN101910414B (zh) * | 2007-11-07 | 2016-01-13 | 健泰科生物技术公司 | 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物 |
| CN102459639A (zh) | 2009-04-18 | 2012-05-16 | 健泰科生物技术公司 | 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法 |
| US9085798B2 (en) | 2009-04-30 | 2015-07-21 | Prognosys Biosciences, Inc. | Nucleic acid constructs and methods of use |
| US9273118B2 (en) | 2009-07-15 | 2016-03-01 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| SG10201405069QA (en) * | 2009-08-25 | 2014-10-30 | Berg Llc | Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10) |
| WO2011127099A1 (en) | 2010-04-05 | 2011-10-13 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
| CN102947706B (zh) * | 2010-04-19 | 2018-04-13 | 生物标志物策略公司 | 预测药物敏感性、抗性和疾病进展的组合物和方法 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| CN103429615B (zh) | 2010-12-02 | 2018-03-16 | 埃姆医疗有限公司 | 用于生产高亲和力抗体的方式和方法 |
| EP2694709B1 (en) | 2011-04-08 | 2016-09-14 | Prognosys Biosciences, Inc. | Peptide constructs and assay systems |
| GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
| ES2709654T3 (es) | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| EP4592400A3 (en) | 2012-10-17 | 2025-10-29 | 10x Genomics Sweden AB | Methods and product for optimising localised or spatial detection of gene expression in a tissue sample |
| KR102270618B1 (ko) | 2012-10-30 | 2021-06-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| EP3736573A1 (en) * | 2013-03-15 | 2020-11-11 | Prognosys Biosciences, Inc. | Methods for detecting peptide/mhc/tcr binding |
| CA2916662C (en) | 2013-06-25 | 2022-03-08 | Prognosys Biosciences, Inc. | Methods and systems for determining spatial patterns of biological targets in a sample |
| US10288608B2 (en) | 2013-11-08 | 2019-05-14 | Prognosys Biosciences, Inc. | Polynucleotide conjugates and methods for analyte detection |
| WO2015085171A1 (en) * | 2013-12-06 | 2015-06-11 | Adventist Health Systems/Sunbelt, Inc. | Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation |
| CA2938193C (en) | 2014-01-31 | 2023-05-02 | Aimm Therapeutics B.V. | Means and methods for producing stable antibodies |
| ES2833543T3 (es) * | 2014-10-24 | 2021-06-15 | Koninklijke Philips Nv | Evaluación de la actividad de la ruta de señalización celular de TGF usando modelos matemáticos de la expresión de genes diana |
| EP3901282B1 (en) | 2015-04-10 | 2023-06-28 | Spatial Transcriptomics AB | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
| WO2017024019A1 (en) * | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| DK3359688T3 (da) * | 2015-10-05 | 2021-08-23 | Biogen Ma Inc | Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme |
| CN114755412A (zh) * | 2016-10-23 | 2022-07-15 | 伯克利之光生命科技公司 | 筛选b细胞淋巴细胞的方法 |
| US20210215697A1 (en) * | 2018-05-14 | 2021-07-15 | Bergenbio Asa | Serum Biomarkers |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| WO2020243579A1 (en) | 2019-05-30 | 2020-12-03 | 10X Genomics, Inc. | Methods of detecting spatial heterogeneity of a biological sample |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
| EP4414459B1 (en) | 2020-05-22 | 2025-09-03 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
| EP4600376A3 (en) | 2020-06-02 | 2025-10-22 | 10X Genomics, Inc. | Spatial transcriptomics for antigen-receptors |
| AU2021283174A1 (en) | 2020-06-02 | 2023-01-05 | 10X Genomics, Inc. | Nucleic acid library methods |
| EP4421186B1 (en) | 2020-06-08 | 2025-08-13 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| CN113684180B (zh) * | 2021-08-31 | 2023-05-26 | 山东大学第二医院 | 一种提高骨髓瘤杀伤活性的nk细胞制备方法 |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| CN115845063B (zh) * | 2022-12-20 | 2024-07-09 | 中国医学科学院医学生物学研究所 | 与急性t淋巴细胞白血病治疗相关的靶点cd40lg及其应用 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024173352A2 (en) * | 2023-02-13 | 2024-08-22 | Shattuck Labs, Inc. | Methods of treating cancer with a sirp1a-based chimeric protein |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2330916C (en) * | 1998-05-19 | 2011-04-05 | Research Development Foundation | Triterpene compositions and methods for use thereof |
| AU2001259142C1 (en) | 2000-04-25 | 2006-11-23 | Biogen Idec Inc. | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| EP1322383B9 (en) * | 2000-10-02 | 2006-09-06 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| AU2003304386A1 (en) * | 2002-10-30 | 2005-02-25 | The Center For Blood Research, Inc. | Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
| JP4609930B2 (ja) * | 2002-12-11 | 2011-01-12 | ベンタナ・メディカル・システムズ・インコーポレーテッド | Ｈｅｒ−２指向性治療に対する応答を予測する方法 |
| GB0301566D0 (en) * | 2003-01-23 | 2003-02-26 | Eirx Therapeutics Ltd | Kinasaes and GPCRs involved in apoptosis |
| ATE447412T1 (de) * | 2003-11-04 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| WO2005044307A2 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Methods of therapy for b cell-related cancers |
| US20090215895A1 (en) * | 2004-01-30 | 2009-08-27 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| US20070292439A1 (en) * | 2004-04-27 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| AU2006247067B2 (en) * | 2005-05-18 | 2012-06-07 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling |
-
2006
- 2006-05-18 AU AU2006247067A patent/AU2006247067B2/en not_active Ceased
- 2006-05-18 WO PCT/US2006/019414 patent/WO2006125143A2/en not_active Ceased
- 2006-05-18 EP EP06770643A patent/EP1894012A2/en not_active Withdrawn
- 2006-05-18 US US11/914,714 patent/US8337851B2/en not_active Expired - Fee Related
- 2006-05-18 CA CA002608751A patent/CA2608751A1/en not_active Abandoned
- 2006-05-18 JP JP2008512536A patent/JP5208730B2/ja not_active Expired - Fee Related
-
2012
- 2012-12-13 JP JP2012272271A patent/JP2013057686A/ja active Pending
- 2012-12-17 US US13/717,175 patent/US20130230528A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008539794A5 (cg-RX-API-DMAC7.html) | ||
| Lim et al. | Inflammatory breast cancer biology: the tumour microenvironment is key | |
| Bertrand et al. | TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma | |
| Padro et al. | Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia | |
| Rassouli et al. | Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma | |
| Jones et al. | Cytokines in cancer drug resistance: Cues to new therapeutic strategies | |
| Mantovani et al. | Tumour-associated macrophages as treatment targets in oncology | |
| Koornstra et al. | Expression of TRAIL (TNF‐related apoptosis‐inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas | |
| JP5409628B2 (ja) | 抗ｔｗｅａｋ受容体抗体の治療上の使用 | |
| Rizzo et al. | New insights into the molecular pathogenesis of langerhans cell histiocytosis | |
| Yin et al. | RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response | |
| KR102739338B1 (ko) | 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법 | |
| Lassen et al. | A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers | |
| Devan et al. | Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma | |
| CN112955748A (zh) | 治疗癌症的方法 | |
| EP2652507A2 (en) | Detecting cancer with anti-ccl25 and anti-ccr9 antibodies | |
| WO2013103637A1 (en) | Analysis and targeting of ror2 in cancer | |
| JP2024511373A (ja) | がんのためのバイオマーカーおよびその使用 | |
| Meulendijks et al. | Exposure and tumor Fn14 expression as determinants of pharmacodynamics of the anti-TWEAK monoclonal antibody RG7212 in patients with Fn14-positive solid tumors | |
| Ye et al. | Enavatuzumab, a humanized anti‐TWEAK receptor monoclonal antibody, exerts antitumor activity through attracting and activating innate immune effector cells | |
| CN112424608A (zh) | 用于疾病的预后和管理的方法 | |
| Wada et al. | Expression of BAFF‐R and TACI in reactive lymphoid tissues and B‐cell lymphomas | |
| Bedewy et al. | CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma | |
| EP2898330B1 (en) | Predicting the sensitivity of a subject to chemotherapy | |
| WO2024249894A9 (en) | Biomarkers for predicting cancer treatment efficacy |